Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnpario Regulatory News (ANP)

Share Price Information for Anpario (ANP)

Share Price is delayed by 15 minutes
Get Live Data
520.00    5.00 (0.97%)
Bid:
510.00
Ask:
530.00
Spread: 20.00 (3.922%)
Market Cap: £85.47m
ANP Live PriceLast checked at - London Stock Exchange

Intraday Anpario Share Chart

Acquisition

30 Mar 2012 07:00

Anpario plc ("Anpario", the "Company" or the "Group")

Acquisition of Meriden Animal Health Limited

Highlights

Acquisition of Meriden Animal Health Limited ("Meriden") for up to £4.125 million Meriden's 2011 sales and adjusted profit before interest and tax were £5.35 million and £740,000 respectively Expected to be immediately earnings enhancing Deal increases Anpario's global market share and significantly strengthens its position in China Consideration to be met from the Company's existing cash resources

Anpario plc, one of the leading suppliers of natural high performance feed additives to enhance health, growth and sustainability in global agriculture and aquaculture markets, is pleased to announce the acquisition of Meriden Animal Health Limited for a total consideration of up to £4.125 million.

The acquisition of Meriden brings another strong trading brand to the Anpario Group, broadening its product technology and increasing Anpario's global market share in the feed additive sector.

Meriden based in Bedfordshire in the United Kingdom, supplies the global agriculture and aquaculture markets with natural animal feed additive products. Meriden's Orego-Stim range of products, using essential oils, is the leading brand in its field and is marketed across 60 countries worldwide, with the majority of sales being outside the United Kingdom

Meriden's sales for the 12 months to December 2011 were £5.35 million and adjusted profit before interest and tax was £740,000. Net assets acquired will be at least £1.644 million, the majority being working capital, including cash in excess of £400,000. The acquisition is expected to be immediately earnings enhancing to the Group as a whole.

Meriden has ten full time staff including a technical support team based in a representative office in Malaysia. The majority of production is outsourced to a third party manufacturer based in the United Kingdom. Meriden typically supplies through distributors in the local territories except Australia where the company has a joint venture company.

Meriden has a close and important partnership with its China operation with sales accounting for 26% of Meriden's total sales during 2011. The China business has been growing well and Anpario intends to give further support to this relationship to capitalise on the vast potential of China's agriculture market.

In line with Anpario's strategy, Meriden will be run as a separate business enabling the team to focus on selling and marketing high quality feed additive products around the world. Joining Anpario means Meriden's management team will gain additional support and can benefit from working together with Anpario's research and development resource to develop new and innovative products for sale under the Meriden brand.

The two shareholders and founders, namely, Stephen Harris, Managing Director, and Pamela McLaren, Company Secretary, are to remain with the business in their existing roles and will continue to develop the Meriden business further.

The price payable for Meriden is on a debt free basis but will include estimated excess cash of £400,000. An initial payment of £3.0 million in cash on completion has been made from existing cash resources. The remaining £1.125 million is payable over the next two years, dependent on Meriden achieving certain performance criteria, and of this, £125,000 is to be satisfied by the issue of ordinary shares of Anpario to Meriden's shareholders. Subsequent to the completion of this acquisition, Anpario's cash balances will be in excess of £2.5 million.

The Company expects to announce its results for the year ended 31 December 2011 on 26 April 2012.

Richard Edwards, Executive Vice Chairman of Anpario, commented:

"Meriden Animal Health is a quality business with strong brand recognition for developing 100% natural feed additives. This acquisition increases our global market share in animal feed additives which is benefiting as the agriculture industry looks to use natural based solutions to promote the health and growth of animals for meat consumption.

Meriden's significant presence in China increases our involvement in the world's biggest producer of poultry and pig meat and reinforces our strategy to build more significant positions in emerging agriculture and aquaculture markets. We are delighted to welcome the Meriden team and very much look forward to working with them in achieving continued success with the business."

Enquiries:

Anpario plcRichard Edwards, Executive Vice Chairman +44 (0)7776 417129Karen Prior, Group Finance Director +44 (0)1909 537380

FinnCap +44 (0)20 7600 1658Matthew Robinson / Henrik Persson - Corporate FinanceStephen Norcross - Corporate Broking

Copyright Business Wire 2012

Date   Source Headline
18th Jun 202612:35 pmRNSResult of AGM
18th Jun 20267:00 amRNSAGM Statement
11th Jun 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
10th Jun 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
9th Jun 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
3rd Jun 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
2nd Jun 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
28th May 20267:00 amRNSPosting of Annual Report and Notice of AGM
20th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
19th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
18th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
15th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
14th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
13th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
12th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
11th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
8th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
7th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
6th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
5th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
1st May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
30th Apr 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
29th Apr 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
28th Apr 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
27th Apr 20267:00 amRNSLaunch of Share Buyback Programme
10th Apr 202612:00 pmRNSInvestor Presentation via Investor Meet Company
31st Mar 20267:00 amRNSFinal Results
3rd Mar 20267:00 amRNSHolding(s) in Company
19th Jan 20263:44 pmRNSBlock listing return
19th Jan 20267:00 amRNSFull year trading statement
23rd Sep 20257:00 amRNSChange of Auditor
10th Sep 20257:00 amRNSInterim Results
9th Sep 202511:36 amRNSInvestor Presentation via Investor Meet Company
22nd Jul 20257:00 amRNSJSOP Awards and TVR
17th Jul 20251:15 pmRNSBlock listing return
19th Jun 20252:01 pmRNSResult of AGM
19th Jun 20257:00 amRNSAGM Statement
19th May 20255:33 pmRNSPosting of Annual Report and Notice of AGM
2nd May 20257:00 amRNSInvestor Presentation via Investor Meet Company
8th Apr 20257:00 amRNSTransaction in Own Shares
7th Apr 20257:00 amRNSLaunch of Share Buyback Programme
2nd Apr 20257:00 amRNSAward Exercise, Voting Rights & Director Dealing
31st Mar 20257:00 amRNSFinal Results
26th Mar 20257:00 amRNSUpdate on Timing of Full Year Results Announcement
15th Jan 20257:00 amRNSGrant of options under SAYE Scheme
10th Jan 20257:00 amRNSFull year trading statement
9th Jan 20257:00 amRNSTotal Voting Rights
16th Dec 20247:00 amRNSExercise of Options and Director/PDMR Shareholding
16th Dec 20247:00 amRNSLaunch of SAYE Scheme
29th Nov 20247:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.